Ok I get it a bit better now. Regardless of how good ONCE treatment proves to be, it won't work in all patients and hopefully QURE can work in these. Doesn't matter if QURE treatment is a lot inferior as long as it works in those patients that ONCE treatment does not.
Any hard numbers out there on estimates of number of patients AAV5 vector could work in versus AAV8? Also, curious what competition looks like for QURE in hemophilia B with AAV5 vector specifically if you know.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.